Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
Did you mean: (eltrombopag)?
39 results
  • Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists. [Review]
    Hepatol Commun 2019; 3(11):1423-1434Nilles KM, Caldwell SH, Flamm SL
  • Thrombocytopenia is common in patients with advanced liver disease. These patients frequently require invasive diagnostic or therapeutic procedures in the setting of thrombocytopenia. A common platelet goal before such procedures is ≥50,000/μL, but target levels vary by provider and the procedure. Platelet transfusion has disadvantages, including safety and cost. No other short-term options for a…
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Hematologic Growth Factors [BOOK]
    National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • The hematologic growth factors (also called stimulating factors) are polypeptides that interact with cell surface receptors on hematologic progenitor cells causing their activation, proliferation and differentiation into mature circulating cells such as red blood cells, white blood cells, neutrophils, monocytes, macrophages and platelets. Several recombinant hematologic growth factors or agonists…
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Thrombopoietin Receptor Agonists [BOOK]
    National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • The thrombopoietin receptor agonists mimic the action of thrombopoietin on its receptor and stimulate the activation, proliferation and maturation of megakaryocytes, resulting in an increase in circulating platelet counts. Thrombopoietin itself acts in this manner, but when recombinant thrombopoietins were used clinically, they were found to cause rebound thrombocytopenia, probably due to inducti…
  • Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. [Review]
    J Blood Med 2019; 10:313-321Cheloff AZ, Al-Samkari H
  • Avatrombopag is an orally-administered small molecule thrombopoietin receptor agonist. It was the third thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia and the first approved to treat periprocedural thrombocytopenia in patients with chronic liver disease (thereby providing an alternative to blood transfusions for these patients). Unlike eltrombopag, avatrombo…
  • Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs. [Review]
    Eur J Haematol 2019; 103(6):531-541Witkowski M, Witkowska M, Robak T
  • Immune thrombocytopenia (ITP) is an autoimmune disease characterized by platelet destruction and reduced platelet production resulting in decreased platelet level and an increased risk of bleeding. Based on the immunologic mechanism of ITP, front-line standard therapy consists of corticosteroids and intravenous immunoglobulins (IVIG). If patients do not respond to the first-line treatment, or if …
  • Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists. [Journal Article]
    Gastroenterol Hepatol (N Y) 2019; 15(6):326-332Miller JB, Figueroa EJ, … Shah NL
  • Thrombocytopenia is a common complication of chronic liver disease and creates clinical challenges for patients who need invasive procedures. Options available to increase platelet counts were previously limited to risk-laden therapies such as platelet transfusions, splenic artery embolization, and transjugular intrahepatic portosystemic shunts. Thrombopoietin (TPO) agonists can augment platelet …
  • Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. [Review]
    Expert Rev Clin Pharmacol 2019; 12(9):859-865Xu H, Cai R
  • Introduction: Thrombocytopenia is a common hematological abnormality in patients with chronic liver disease (CLD), occurring in 64%~84% of patients with cirrhosis or fibrosis. Due to the increased risk of bleeding, thrombocytopenia potentially affects management of CLD, such as surgery or liver biopsy. Avatrombopag is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and i…
New Search Next